Another Surging Pharma Stock to Watch Right Now

Eli Lilly (LLY) stock surged 7.2% to $821.20, its best daily gain since April, after securing an exemption from President Trump's new 100% tariffs on imported branded pharmaceutical products due to its $27 billion U.S. manufacturing expansion. This policy-driven competitive advantage has spurred significant bullish options activity, with call volume quadrupling the daily average and a 50-day put/call ratio at a one-year high, despite traders pricing in low volatility expectations.

Analysis

Eli Lilly (LLY) stock has experienced a significant 7.2% surge to $821.20, marking its best daily performance since April, driven by a key policy development. The company has secured an exemption from a new 100% tariff on imported branded pharmaceuticals, a direct result of its $27 billion investment in expanding U.S. manufacturing facilities. This exemption provides LLY with a distinct competitive advantage over peers potentially impacted by the new levies. From a technical standpoint, the stock is trading at its highest level since June and is approaching its 320-day moving average, a notable resistance point in July. Despite the recent rally, the stock remains 7.1% lower on a year-over-year basis. Market sentiment has turned sharply bullish, evidenced by options volume running at quadruple the daily average, with calls outnumbering puts significantly. This is further highlighted by heavy buying of short-dated weekly 800- and 820-strike calls. Interestingly, this acute bullishness contrasts with a 50-day put/call ratio at a one-year high, indicating a dramatic sentiment reversal. Furthermore, the Schaeffer's Volatility Index (SVI) of 31% ranks in the low 17th percentile, suggesting that options are relatively inexpensive and the market is pricing in low volatility expectations despite the major news catalyst.

Key Decisions for Investors

• Given the policy-driven competitive advantage and strong momentum, investors should evaluate the potential for further upside, especially as the stock remains below its prior year levels.
• Traders should closely monitor the stock's interaction with the 320-day moving average, as a sustained break above this historical resistance could signal the confirmation of a new uptrend.
• The combination of surging bullish options activity and low implied volatility may present a tactical opportunity for purchasing call options to speculate on further gains at a relatively low cost.
• Consider the tariff exemption not just as a short-term catalyst but as a reflection of a long-term strategic positive, as the $27 billion U.S. investment de-risks the supply chain from future geopolitical tensions.